# Consolidative Radiotherapy for Metastatic Urothelial Bladder Cancer Patients Without Progression and With no More Than Three Residual Metastatic Lesions Following First Line Systemic Therapy

> **NCT04428554** · PHASE2 · RECRUITING · sponsor: **Institut Claudius Regaud** · enrollment: 130 (estimated)

## Conditions studied

- Urothelial Bladder Cancer

## Interventions

- **RADIATION:** Experimental arm

## Key facts

- **NCT ID:** NCT04428554
- **Lead sponsor:** Institut Claudius Regaud
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-06-30
- **Primary completion:** 2031-07
- **Final completion:** 2031-07
- **Target enrollment:** 130 (ESTIMATED)
- **Last updated:** 2025-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04428554

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04428554, "Consolidative Radiotherapy for Metastatic Urothelial Bladder Cancer Patients Without Progression and With no More Than Three Residual Metastatic Lesions Following First Line Systemic Therapy". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT04428554. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*